#1 Clinical Trials Search in Europe

Tazemetostat

Tazemetostat is an emerging drug being studied in various clinical trials for its potential in treating different types of cancer. This article explores the use of tazemetostat in clinical trials, focusing on its applications, efficacy, and safety profile across multiple cancer types.

Table of Contents

What is Tazemetostat?

Tazemetostat is a medication used in the treatment of various types of cancer. It is also known by other names such as EPZ-6438, E7438, IPN60200, and TAZVERIK[1][2]. Tazemetostat is a type of drug called a small molecule inhibitor, which means it works by blocking specific processes in cancer cells[3].

How Does Tazemetostat Work?

Tazemetostat targets a protein in cells called EZH2 (enhancer of zeste homolog 2). EZH2 is an enzyme that plays a role in controlling which genes are active or inactive in cells. In some types of cancer, EZH2 becomes overactive, leading to uncontrolled cell growth. By inhibiting EZH2, tazemetostat aims to slow down or stop the growth of cancer cells[3].

What Conditions Does Tazemetostat Treat?

Tazemetostat has shown promise in treating several types of cancer, including:

  • Follicular Lymphoma (FL): A type of slow-growing blood cancer that affects white blood cells called B-cells[1][2].
  • Diffuse Large B-cell Lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma that also affects B-cells[1][2].
  • Epithelioid Sarcoma (ES): A rare type of soft tissue cancer[1][2].
  • Synovial Sarcoma: Another type of soft tissue cancer that typically occurs near joints[1][2].
  • Malignant Rhabdoid Tumors: Rare and aggressive cancers that can occur in various parts of the body, especially in children[4].
  • INI1-negative tumors: Cancers that lack a specific protein called INI1, which helps control cell growth[4].

Tazemetostat is particularly useful for treating cancers that have returned after previous treatment (relapsed) or have not responded well to other treatments (refractory)[1][2].

Administration and Dosage

Tazemetostat is typically taken orally (by mouth) in the form of tablets. The usual adult dose is 800 mg twice daily, but this can vary depending on the specific condition being treated and the patient’s individual needs[1][2]. For children aged 12-17, the dose may be adjusted based on body surface area (520 mg/m2/dose twice daily)[5]. Treatment cycles usually last 28 days and may continue for up to 2 years or until the disease progresses or side effects become unmanageable[5].

Ongoing Research

Researchers are currently studying tazemetostat’s effectiveness in treating other types of cancer, including:

  • Solid tumors with ARID1A mutations: ARID1A is a gene that, when mutated, can contribute to cancer growth. Studies are exploring whether tazemetostat can help patients with various solid tumors that have this mutation[6].
  • Malignant Peripheral Nerve Sheath Tumors (MPNST): These are rare cancers that develop in the protective covering of nerves[5].
  • COVID-19-related complications: Interestingly, one study is investigating whether tazemetostat could help treat severe inflammatory reactions in COVID-19 patients[7].

Potential Side Effects

Like all medications, tazemetostat can cause side effects. Common side effects may include:

  • Fatigue
  • Nausea
  • Decreased appetite
  • Changes in blood cell counts
  • Muscle and bone pain

Your healthcare team will monitor you closely for any side effects and adjust your treatment if necessary[1][2].

Drug Interactions

Tazemetostat can interact with other medications. Specifically:

  • Strong CYP3A inhibitors (like itraconazole): These drugs can increase the levels of tazemetostat in your body, potentially increasing side effects[8].
  • Strong CYP3A inducers (like rifampin): These drugs can decrease the levels of tazemetostat in your body, potentially making it less effective[8].

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions[8].

Aspect Details
Drug Name Tazemetostat (also known as EPZ-6438, E7438)
Mechanism of Action Selective small molecule inhibitor of EZH2 (enhancer of zeste homolog 2)
Cancer Types Studied B-cell lymphomas (follicular lymphoma, diffuse large B-cell lymphoma), solid tumors, epithelioid sarcoma, synovial sarcoma, malignant mesothelioma
Administration Oral tablets, typically 800 mg twice daily in 28-day cycles
Primary Outcomes Objective response rate (ORR), progression-free survival (PFS), safety and tolerability, pharmacokinetic parameters
Notable Trials NCT01897571, NCT02875548, NCT02860286, NCT03009344
Safety Considerations Monitored for adverse events, specific concerns vary by cancer type and patient population
Potential Biomarkers EZH2 mutations, BAP1 loss of function (in mesothelioma)

FAQ

  • What is tazemetostat and how does it work? Tazemetostat is a selective small molecule inhibitor of EZH2 (enhancer of zeste homolog 2), a histone-lysine methyltransferase enzyme. It works by inhibiting EZH2, which plays a role in gene expression and is often overexpressed in certain cancers.
  • What types of cancer is tazemetostat being studied for? Tazemetostat is being studied for various cancers, including B-cell lymphomas (such as follicular lymphoma and diffuse large B-cell lymphoma), solid tumors, epithelioid sarcoma, synovial sarcoma, and malignant mesothelioma.
  • How is tazemetostat administered in clinical trials? In most trials, tazemetostat is administered orally, typically as tablets. The dosage varies, but common doses include 800 mg twice daily in continuous 28-day cycles.
  • What are some of the primary outcomes being measured in tazemetostat trials? Primary outcomes often include objective response rate (ORR), progression-free survival (PFS), safety and tolerability (measured by adverse events), and pharmacokinetic parameters such as maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC).
  • Are there any notable side effects or safety concerns with tazemetostat? While safety profiles vary between trials, common adverse events are monitored. The specific safety concerns depend on the cancer type and patient population being studied. Detailed safety information should be discussed with healthcare providers.

Ongoing Clinical Trials on Tazemetostat

  • Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Hungary Italy Poland +1

  • Study on the Safety and Effects of CC-92480 with Dexamethasone and Drug Combinations for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Norway Spain

  • Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Study on the Effects of Durvalumab and Tazemetostat for Adults with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Poland

Glossary

  • EZH2: Enhancer of zeste homolog 2, a histone-lysine methyltransferase enzyme that plays a role in gene expression and is often overexpressed in certain cancers.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body, including measurements like maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC).
  • Objective Response Rate (ORR): The proportion of patients who achieve either a complete response or partial response to treatment, as measured by standardized criteria.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose during a clinical trial.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects, determined during the dose-escalation phase of a clinical trial.
  • BAP1: BRCA1 Associated Protein 1, a tumor suppressor gene that, when mutated, can be associated with certain cancers like mesothelioma.
  • Cytokine Release Syndrome: A systemic inflammatory response that can occur as a side effect of certain cancer treatments, characterized by fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing.

References

  1. https://clinicaltrials.gov/study/NCT01897571
  2. https://clinicaltrials.eu/trial/56496/
  3. https://clinicaltrials.gov/study/NCT03009344
  4. https://clinicaltrials.gov/study/NCT05407441
  5. https://clinicaltrials.gov/study/NCT04917042
  6. https://clinicaltrials.gov/study/NCT05023655
  7. https://clinicaltrials.gov/study/NCT05018975
  8. https://clinicaltrials.gov/study/NCT04537715